Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 44 citing articles:

COVID-19 Self-Test Data: Challenges and Opportunities — United States, October 31, 2021–June 11, 2022
Matthew D. Ritchey, Hannah G. Rosenblum, Kim Del Guercio, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 32, pp. 1005-1010
Open Access | Times Cited: 42
Projecting Omicron scenarios in the US while tracking population-level immunity
Anass Bouchnita, Kaiming Bi, Spencer J. Fox, et al.
Epidemics (2024) Vol. 46, pp. 100746-100746
Open Access | Times Cited: 6
Tracking Immunity: An Increased Number of COVID-19 Boosters Increases the Longevity of Anti-RBD and Anti-RBD-Neutralizing Antibodies
Ching‐Wen Hou, Stacy Williams, Veronica Boyle, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 61-61
Open Access
Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers
Dunia Hatabah, Sneh Lata Gupta, Grace Mantus, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 163-163
Open Access
Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development
Shô Miyamoto, Tadaki Suzuki
Vaccine (2024) Vol. 42, Iss. 6, pp. 1401-1406
Closed Access | Times Cited: 4
Long-Term Symptoms Associated With SARS-CoV-2 Infection Among Blood Donors
Melisa M. Shah, Bryan R. Spencer, Jade James-Gist, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e245611-e245611
Open Access | Times Cited: 4
Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage
Joseph A. Lewnard, Parag Mahale, Deborah E. Malden, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Infectious disease surveillance needs for the United States: lessons from Covid-19
Marc Lipsitch, Mary T. Bassett, John S. Brownstein, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 3
Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection
Ryan E. Wiegand, Bruce Fireman, Morgan Najdowski, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Editorial: Current research on serological analyses of infectious diseases
Eric Rogier, Emanuele Giorgi, Kevin K. A. Tetteh, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 7
Comparison of COVID-19 home-testers vs. laboratory-testers in New York State (excluding New York City), November 2021 to April 2022
Vajeera Dorabawila, Virgile Barnes, Nirmala Ramesh, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 6
Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave
Maja Sočan, Katarina Prosenc, Maja Mrzel
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 4, pp. 3665-3665
Open Access | Times Cited: 5
Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan
Seiya Yamayoshi, Etsuko Nagai, Keiko Mitamura, et al.
Epidemiology and Infection (2024) Vol. 152
Open Access | Times Cited: 1
Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021–February 2022
Tina J. Benoit, Yun Kim, Yangyang Deng, et al.
Public Health Reports (2024) Vol. 139, Iss. 4, pp. 501-511
Closed Access | Times Cited: 1
Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023
Ryo Kinoshita, Shô Miyamoto, Shoko Sakuraba, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 6
Open Access | Times Cited: 1
Convalescent Plasma and Other Antibody Therapies for Infectious Diseases—Lessons Learned from COVID-19 and Future Prospects
David J. Sullivan
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Serological testing for SARS-CoV-2: Advancements and future challenges
Harry Alexopoulos, Ioannis P. Trougakos, Meletios Α. Dimopoulos, et al.
European Journal of Internal Medicine (2022) Vol. 108, pp. 104-105
Open Access | Times Cited: 8
Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence
Bernard S. Black, David Thaw
Microorganisms (2023) Vol. 12, Iss. 1, pp. 89-89
Open Access | Times Cited: 4
Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adults
Denis Nash, Avantika Srivastava, Yanhan Shen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
SARS-CoV-2 Seroprevalence and Vaccine Uptake among Pregnant Women at First Antenatal Care Visits in Malawi
Lyson Tenthani, Victoria Seffren, Alinune N. Kabaghe, et al.
American Journal of Tropical Medicine and Hygiene (2024) Vol. 110, Iss. 5, pp. 989-993
Open Access | Times Cited: 1
Cohort profile: follow-up of a household cohort throughout five epidemic waves of SARS-CoV-2 in Rio de Janeiro, Brazil
Michele Fernanda Borges da Silva, Lusiele Guaraldo, Heloísa Ferreira Pinto Santos, et al.
Cadernos de Saúde Pública (2024) Vol. 40, Iss. 7
Open Access | Times Cited: 1
Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19—Reply
Matthew W. McCarthy, Christopher J. Lindsell, Susanna Naggie
JAMA (2023) Vol. 329, Iss. 19, pp. 1702-1702
Closed Access | Times Cited: 3
Transition to endemic: 2-year SARS-CoV-2 surveillance follow-up of the ELISA cohort
Bandik Föh, Maike Schnoor, Alexander Balck, et al.
ERJ Open Research (2023) Vol. 9, Iss. 4, pp. 00746-2022
Open Access | Times Cited: 3
Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer
Ananda M. Rodilla, Rajesh M. Valanparambil, Philip C. Mack, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1838-1840
Open Access | Times Cited: 3
Seroprevalence and clinical characteristics of SARS‐CoV‐2 infection in children with cystic fibrosis
Georgene E. Hergenroeder, Anna Faino, Jonathan D. Cogen, et al.
Pediatric Pulmonology (2023) Vol. 58, Iss. 9, pp. 2478-2486
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top